Shalini Andersson, PhD

Vice President of Oligonucleotide Discovery at AstraZeneca

Speaker

Shalini is Vice President of Nucleic Acid Therapeutics within AstraZeneca’s BioPharmaceuticals R&D, where she leads global strategy and innovation across oligonucleotides, mRNA therapies, gene engineering and targeted delivery platform.

She is highly experienced in drug discovery, development, and strategic leadership, fostering collaborations with external partners and academia. Previously, she led teams in Medicinal Chemistry and Drug Metabolism & Pharmacokinetics for cardiovascular, renal and metabolic therapies. Shalini serves on several scientific boards and advisory groups.

Shalini earned her PhD at the University of Linköping, Sweden, where she also held faculty research and teaching positions prior to transitioning to industry. She has published more than 70 peer-reviewed articles and holds eight patents.